Deutsche Märkte geschlossen

Bavarian Nordic A/S (BV3.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
41,67-0,75 (-1,77%)
Ab 03:35PM CET. Markt geöffnet.

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
http://www.bavarian-nordic.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter711

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Paul ChaplinCEO & Pres1,16MN/A1967
Mr. Henrik Juuel M.Sc.CFO & Exec. VP445,05kN/A1965
Mr. Henrik BirkCOO & Exec. VP509,54kN/A1974
Dr. Tommi Kainu M.D., Ph.D.Exec. Officer554,35kN/A1972
Mr. Rolf Sass SørensenVP of Investor Relations & CommunicationsN/AN/AN/A
Ms. Anu Helena KernsExec. VP & Chief People OfficerN/AN/AN/A
Mr. Jean-Christophe MayExec. VP & Chief Commercial OfficerN/AN/A1967
Dr. Laurence De MoerloozeExec. VP & Chief Scientific OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2018 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.

Corporate Governance

Bavarian Nordic A/Ss ISS Governance QualityScore, Stand 30. Juni 2021, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 3, Shareholderrechte: 1, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.